TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2878678

Group type: EXPERIMENTAL
Intervention: Bufuralol 7.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bufuralol 15 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bufuralol 30 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bufuralol 60 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bufuralol 120 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29289702

Group type: EXPERIMENTAL
Intervention: Financial incentives for dietary self-monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Financial incentives for interim weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of financial incentives for dietary self-monitoring and interim weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: No financial incentives for dietary self-monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: No financial incentives for interim weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: No financial incentives for both dietary self-monitoring and interim weight loss
Number of subjects: 0
Study: 25780997

Group type: EXPERIMENTAL
Intervention: Spray cryotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study: 23157542

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Power-type resistance training (RT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 144
Study: 22291074

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 2616

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 2616
Study: 21533288

Group type: EXPERIMENTAL
Intervention: Decision aid about bisphosphonates
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual primary care (Control)
Number of subjects: 18
Study: 20329382

Group type: EXPERIMENTAL
Intervention: Standard MDT + once a month supervised 100 mg of Minocycline and 400 mg of Ofloxacin for 12 months
Number of subjects: 100
Study: 16520446

Group type: EXPERIMENTAL
Intervention: Baseline past-week depressive symptomatology (dichotomous)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Baseline past-week depressive symptomatology (continuous)
Number of subjects: 1659
Study: 12973820

Group type: EXPERIMENTAL
Intervention: Modified-release methylphenidate (Ritalin LA) 40 mg administered intact with a high-fat breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified-release methylphenidate (Ritalin LA) 40 mg sprinkled on applesauce
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting condition (control group)
Number of subjects: 0
Study: 11885169

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)‐coated implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non‐coated implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non‐coated implants in bone quality 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non‐coated implants in bone quality 4
Number of subjects: 0
Study: 9003951

Group type: EXPERIMENTAL
Intervention: 5% oxatomide gel
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (petrolatum ointment)
Number of subjects: 22
Study: 1510262

Group type: EXPERIMENTAL
Intervention: DDAVP (10 micrograms/m2 of body surface area)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physiologic saline solution (placebo group)
Number of subjects: 30
Study: 6239548

Group type: EXPERIMENTAL
Intervention: Topical anesthesia applied to the fallopian tubes
Number of subjects: 300

Group type: COMPARATOR
Intervention: No topical anesthesia
Number of subjects: 300
Study: 31724334

Group type: EXPERIMENTAL
Intervention: Monosialotetrahexosylganglioside (GM1)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 30682452

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) treatment
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 6-gene signature (6GS)
Number of subjects: 142
Study: 29071987

Group type: EXPERIMENTAL
Intervention: Double-needle winding and pulling combined with electroacupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine electroacupuncture treatment (Control)
Number of subjects: 60
Study: 25833784

Group type: EXPERIMENTAL
Intervention: Mamba (50 g, 260 kcal, >75% of RDA for critical micronutrients)
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Tablet Yo (42 g, 165 kcal)
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Control group (unfortified cereal bar)
Number of subjects: 1167
Study: 24355804

Group type: EXPERIMENTAL
Intervention: Service-learning environment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21968012

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19379470

Group type: EXPERIMENTAL
Intervention: Double kissing (DK) crush stenting technique
Number of subjects: 312

Group type: COMPARATOR
Intervention: Classical crush stenting technique
Number of subjects: 312
Study: 17408017

Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ) at a 600 mg/day maintenance dose for periods ranging from 15 days to 13 years.
Number of subjects: 54
Study: 15008034

Group type: EXPERIMENTAL
Intervention: Physician-nurse team
Number of subjects: 2

Group type: COMPARATOR
Intervention: Physician-only
Number of subjects: 2
Study: 11317060

Group type: EXPERIMENTAL
Intervention: Herbal medicines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring and assisting in herbal therapeutic decisions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative approach against herbal medicine use
Number of subjects: 0
Study: 9438684

Group type: EXPERIMENTAL
Intervention: Mitomycin/vinblastine/cisplatin regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2 and 250 mg/m2) combined with cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide/cisplatin
Number of subjects: 0
Study: 7517829

Group type: EXPERIMENTAL
Intervention: Intensive drug treatment (combinations of colestipol, nicotinic acid and lovastatin)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Diet and modest doses of colestipol (Control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diet and lovastatin (up to 80 mg daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Diet alone (Control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intensive drug treatment (in women)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Diet alone (in men) (Control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intensive drug treatment (in men)
Number of subjects: 72
Study: 3139326

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NG) therapy
Number of subjects: 310
Study: 31777235

Group type: EXPERIMENTAL
Intervention: 5-time electroacupuncture treatment (once a day for 5 times)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10-time electroacupuncture treatment (once a day for 10 times)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between 5-time and 10-time treatment groups
Number of subjects: 60
Study: 28502496

Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE) under fasted conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE) under low-fat meal conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE) under high-fat meal conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE) under low-fat/high-fat meal conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE)
Number of subjects: 24
Study: 24957913

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied to the common fibular nerve during surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no electrical stimulation)
Number of subjects: 90
Study: 23124244

Group type: EXPERIMENTAL
Intervention: Bifidobacterium species (B. adolescentis, B. bifidum, B. dentium, B. breve, B. longum)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: B. longum
Number of subjects: 87
Study: 20851929

Group type: EXPERIMENTAL
Intervention: ALN-RSV01 (0.6 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ALN-RSV01
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19357741

Group type: EXPERIMENTAL
Intervention: Gemcitabine with radiotherapy (CT/RT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radiotherapy only (RT)
Number of subjects: 80
Study: 17163253

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus ginger
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 120
Study: 14644393

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day for 8 weeks)
Number of subjects: 29
Study: 10770982

Group type: EXPERIMENTAL
Intervention: Pegvisomant 10 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pegvisomant 15 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pegvisomant 20 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 9384476

Group type: EXPERIMENTAL
Intervention: High-dose therapy and autologous stem cell transplantation
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional-dose salvage therapy prior to high-dose therapy
Number of subjects: 139
Study: 9796516

Group type: EXPERIMENTAL
Intervention: Incisive nerve block
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination inferior alveolar nerve block plus incisive nerve block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 4010949

Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31348349

Group type: EXPERIMENTAL
Intervention: Hand therapy (supervised sessions and home exercises); mean 9.2 sessions over 14.2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand therapy (shorter duration)
Number of subjects: 0
Study: 28760939

Group type: EXPERIMENTAL
Intervention: Intensive treatment (<120 mmHg)
Number of subjects: 7879

Group type: COMPARATOR
Intervention: Standard treatment (<140 mmHg)
Number of subjects: 7879

Group type: EXPERIMENTAL
Intervention: Highest quintile of OBPV
Number of subjects: 7879

Group type: EXPERIMENTAL
Intervention: OBPV overall
Number of subjects: 7879

Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretics or dihydropyridine calcium channel blockers
Number of subjects: 7879

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Number of subjects: 7879

Group type: EXPERIMENTAL
Intervention: Composite endpoint of fatal and nonfatal cardiovascular events
Number of subjects: 7879

Group type: EXPERIMENTAL
Intervention: Heart failure or stroke
Number of subjects: 7879
Study: 27983572

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 µg daily for six weeks)
Number of subjects: 76
Study: 24583055

Group type: EXPERIMENTAL
Intervention: Bioimpedance-guided fluid management
Number of subjects: 131

Group type: COMPARATOR
Intervention: Clinical judgment without bioimpedance measures
Number of subjects: 131
Study: 22665533

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² load then 250 mg/m² per week IV)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cetuximab plus carboplatin (area under the curve of 2, once per week IV) after progression
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cetuximab plus carboplatin from the beginning
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cetuximab plus carboplatin
Number of subjects: 102
Study: 19570717

Group type: EXPERIMENTAL
Intervention: Tonabersat 40 mg once daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16709320

Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg twice daily)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Diclofenac (75 mg twice daily)
Number of subjects: 247
Study: 12738704

Group type: EXPERIMENTAL
Intervention: Tailored interventions to support implementation of guidelines
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Increased fee for telephone consultations
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Computerized decision support
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Regular meetings to discuss guidelines
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Internal communication and telephone routines
Number of subjects: 120
Study: 10893353

Group type: COMPARATOR
Intervention: External high-frequency oscillation (EHFO)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure ventilation (INPV)
Number of subjects: 70
Study: 9112295

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 786

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 786
Study: 1546834

Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (2 ml, 1.2 micrograms/ml) three times a day for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3986859

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31412955

Group type: EXPERIMENTAL
Intervention: NI-03 (camostat mesilate) administered three times daily at doses of 100, 200, or 300 mg for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NI-03 (camostat mesilate)
Number of subjects: 0
Study: 29224502

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD)
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
Number of subjects: 1334
Study: 27002665

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (US) group; 3 MHz, 1.5 W/cm2
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham ultrasound group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (TENS + exercise program)
Number of subjects: 50
Study: 24071031

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BPAP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 27
Study: 22453316

Group type: EXPERIMENTAL
Intervention: Docusate sodium plus Miralax, fiber wafers, and bisacodyl suppositories
Number of subjects: 60

Group type: COMPARATOR
Intervention: Docusate sodium
Number of subjects: 60
Study: 20233853

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation for 7.3 years
Number of subjects: 3355
Study: 18821454

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 6
Study: 16015082

Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Transplantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional management (tarsorrhaphy and bandage contact lens)
Number of subjects: 30
Study: 12454554

Group type: EXPERIMENTAL
Intervention: AMI400
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: AMI800
Number of subjects: 319

Group type: COMPARATOR
Intervention: AMI100
Number of subjects: 319

Group type: COMPARATOR
Intervention: HAL16
Number of subjects: 319
Study: 10613592

Group type: EXPERIMENTAL
Intervention: EPO plus G-CSF combination after PBPCT
Number of subjects: 11
Study: 8600497

Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg/d)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Acetaminophen (2,000 mg/d)
Number of subjects: 39
Study: 2007941

Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 50 mg/kg per day for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ampicillin, 100 mg/kg per day for 5 days
Number of subjects: 40
Study: 7102737

Group type: EXPERIMENTAL
Intervention: Advance Organizer with written presentation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Advance Organizer with oral presentation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Traditional introduction with written presentation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Traditional introduction with oral presentation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: No introduction with written presentation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: No introduction with oral presentation
Number of subjects: 96
Study: 30589567

Group type: EXPERIMENTAL
Intervention: Strengthening executive functions through group games (12 sessions of 45 minutes each)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 28831548

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 50 mg/day oral, increased to 2-3 mg/kg/day with oral prednisolone as adjunctive therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Rituximab (RIT) 1 g intravenous, repeated 2 weeks later and then every 6 months
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Rituximab (RIT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 68
Study: 25325508

Group type: EXPERIMENTAL
Intervention: Home single-channel nasal pressure (HNP)
Number of subjects: 787
Study: 23000525

Group type: EXPERIMENTAL
Intervention: Simplified method for complete denture fabrication (Group S)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional method for complete denture fabrication (Group C)
Number of subjects: 39
Study: 21303732

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-MPH), mean daily dose 84.6±31.6 mg (1.04±0.29 mg/kg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo, mean daily dose 100.5±21.9 mg (1.20±0.11 mg/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both OROS-MPH and Placebo
Number of subjects: 87
Study: 19530576

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg intramuscular every 12 hours for 2 doses
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard rescue drugs (Tramadol)
Number of subjects: 80
Study: 17344500

Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 12901874

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (250 mg/day)
Number of subjects: 0
Study: 10475595

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine 5% cream (EMLA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 120
Study: 8712153

Group type: EXPERIMENTAL
Intervention: Cocaine administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1680327

Group type: EXPERIMENTAL
Intervention: Pirbuterol (0.2 mg) in Autohaler
Number of subjects: 17

Group type: COMPARATOR
Intervention: Salbutamol (0.1 mg) in customary metered-dose inhaler
Number of subjects: 17
Study: 7040820

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with DTIC plus intradermal BCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methyl‐CCNU plus intradermal BCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (both groups)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 60
Study: 30920952

Group type: EXPERIMENTAL
Intervention: Clinical reasoning curriculum (six interactive online modules and a skills-based workshop)
Number of subjects: 0
Study: 29094315

Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 µg once daily
Number of subjects: 236

Group type: COMPARATOR
Intervention: Tiotropium/Olodaterol (TIO/OLO) 5/5 µg once daily
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol (UMEC/VI)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Tiotropium/Olodaterol (TIO/OLO)
Number of subjects: 236
Study: 26433562

Group type: EXPERIMENTAL
Intervention: Reduced standard treatment combined with the computer‐based therapeutic education system (TES)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard methadone maintenance treatment
Number of subjects: 160
Study: 23713301

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medication group (clomifene and HCG)
Number of subjects: 50
Study: 21282548

Group type: EXPERIMENTAL
Intervention: Electronic Self‐Report Assessment‐Cancer (ESRA‐C) provided to clinicians before visits (n = 327)
Number of subjects: 660

Group type: COMPARATOR
Intervention: No summary provided to clinicians (Control group, n = 333)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Both groups (ESRA-C and Control)
Number of subjects: 660
Study: 19917523

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) and Vitamin C and E (VCE) supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: No HRT treatment (Control)
Number of subjects: 80
Study: 15975736

Group type: EXPERIMENTAL
Intervention: MDMA (1.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: d-amphetamine (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: mCPP (0.75 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15285969

Group type: EXPERIMENTAL
Intervention: Seeking Safety therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Relapse Prevention therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard Community Care
Number of subjects: 107
Study: 10719574

Group type: EXPERIMENTAL
Intervention: Experimental arroz caldo with 14.84 g total dietary fiber (TDF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control arroz caldo with 3.45 g total dietary fiber (TDF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Experimental arroz caldo
Number of subjects: 10
Study: 8548716

Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine (generic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0